A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Stopped early · Phase 3

Conditions studied: Sexual Dysfunctions, Psychological

In brief

To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire Disorder who have completed a prior clinical trial of flibanserin (Trial 511.130, 511.147, or 511.156).

Key facts

Study ID

NCT01103362

Run by

Sprout Pharmaceuticals, Inc

People needed

596

Starts

2010-04-01

Expected to finish

2011-01-01

Last updated by the study team

2014-05-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women with primary diagnosis of Hypoactive Sexual Desire Disorder (HSDD) who completed a prior trial of flibanserin. Such completion requires compliance with trial medication and the trial visit schedule including any post-treatment visits required in that clinical trial. Early discontinuation for any reason disqualifies the patient from entry into this trial. Patients must enroll in this study within 7 days after completing the final visit of the parent trial.
• The premenopausal patient must use a medically acceptable method of contraception for at least two months before baseline and continue to use medically acceptable method of contraception during the trial.
• Postmenopausal patients must be a naturally postmenopausal woman of any age with at least one ovary. Natural menopause is defined as greater than 12 months of spontaneous amenorrhea.
• In the investigator's opinion, patients must be willing to adhere to trial requirements as well as to be able to perform them.
• Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss sexual functioning with study staff.

You may not qualify if…

• Patients with history of Major Depressive Disorder (MDD) within six months prior to the Screen Visit, or a score of greater than or equal to 14 on the Beck Depression Inventory II (BDI-II), or a history of suicidal behavior or suicidal ideation according to the Columbia-Suicide Severity Rating Scale (C-SSRS®). If a psychiatrist or psychologist, using clinical judgment, believes a patient who scored between 14 and 19 on the BDI®-II is not depressed, the patient may be entered into the trial. NOTE: If a patient reports positive response to BDI®-II Question 9 and/or a Yes response to either C-SSRS® Suicide Ideation section Question 1 and/or 2 and/or any question in the Suicide Behavior section, please refer to Section 5.2.5 for immediate actions required.
• At the Screen Visit, serum alanine aminotransferase, serum aspartate aminotransferase, alkaline phosphatase, or total bilirubin greater than or equal to three times upper limit of normal; blood urea nitrogen greater than or equal to 30 mg/deciliter (dL), plasma creatinine greater than or equal to 2 mg/dL, hemoglobin <9.5 grams/dL, leukopenia (<2.5 x 103/microliter [µL]), neutropenia (<1.5 x 103/µL), lymphopenia (<0.8 x 103/µL), thrombocytopenia (<100 x 103/µL) or thrombocytosis (>500 x 103/µL); or random glucose > upper limit of normal.
• Patients with newly developed, self-reported symptoms after the End of Treatment parent trial visit and at this trial Screen Visit of pelvic inflammatory disease, urinary tract or vaginal infection / vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy.
• Patients with history of any cancer within the last ten years, other than non-invasive, previously resected basal cell carcinoma of the skin.
• Patients whose sexual function was affected by hysterectomy, oophorectomy, or any other pelvic or vaginal surgery.
• Patients who are pregnant (by urine pregnancy test at the Screen Visit) or have been pregnant within the month prior to the Screen Visit or who are breast-feeding or have breast-fed within the last six months prior to the Baseline Visit.
• Patients receiving medication excluded in their prior safety and efficacy trial of flibanserin causing sexual dysfunction or safety-relevant interactions (i.e., antidepressants, anxiolytics, antipsychotics, anticonvulsants, anticoagulants).
• Patients with clinically relevant conditions which might interfere with their ability to participate in the trial.
• Participation in a trial of an investigational medication other than flibanserin within one month prior to the Screen Visit.

Where it is running

• 511.133.01141 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States
• 511.133.01046 Boehringer Ingelheim Investigational Site — Huntsville, Alabama, United States
• 511.133.01042 Boehringer Ingelheim Investigational Site — Mobile, Alabama, United States
• 511.133.01025 Boehringer Ingelheim Investigational Site — Phoenix, Arizona, United States
• 511.133.01073 Boehringer Ingelheim Investigational Site — Phoenix, Arizona, United States
• 511.133.01127 Boehringer Ingelheim Investigational Site — Tuscon, Arizona, United States
• 511.133.01030 Boehringer Ingelheim Investigational Site — Encinitas, California, United States
• 511.133.01028 Boehringer Ingelheim Investigational Site — Fair Oaks, California, United States
• 511.133.01037 Boehringer Ingelheim Investigational Site — Irvine, California, United States
• 511.133.01136 Boehringer Ingelheim Investigational Site — La Mesa, California, United States
• 511.133.01128 Boehringer Ingelheim Investigational Site — Newport Beach, California, United States
• 511.133.01115 Boehringer Ingelheim Investigational Site — Oceanside, California, United States
• 511.133.01022 Boehringer Ingelheim Investigational Site — Sacremento, California, United States
• 511.133.01035 Boehringer Ingelheim Investigational Site — San Diego, California, United States
• 511.133.01052 Boehringer Ingelheim Investigational Site — San Diego, California, United States
• 511.133.01099 Boehringer Ingelheim Investigational Site — San Diego, California, United States
• 511.133.01016 Boehringer Ingelheim Investigational Site — Tarzana, California, United States
• 511.133.01021 Boehringer Ingelheim Investigational Site — Vista, California, United States
• 511.133.01051 Boehringer Ingelheim Investigational Site — Westlake Village, California, United States
• 511.133.01071 Boehringer Ingelheim Investigational Site — Denver, Colorado, United States
• 511.133.01053 Boehringer Ingelheim Investigational Site — Farmington, Connecticut, United States
• 511.133.01015 Boehringer Ingelheim Investigational Site — Groton, Connecticut, United States
• 511.133.01139 Boehringer Ingelheim Investigational Site — New London, Connecticut, United States
• 511.133.01064 Boehringer Ingelheim Investigational Site — Newark, Delaware, United States
• 511.133.01074 Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.